Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Inclusion Criteria:

   - Newly diagnosed disease of 1 of the following histologic types:

      - Focal anaplastic Wilms' tumor

      - Diffuse anaplastic Wilms' tumor

      - Clear cell sarcoma of the kidney

      - Malignant rhabdoid tumor (renal or extrarenal)

      - Renal cell carcinoma

         - Clear cell

         - Papillary

         - Renal medullary

         - Oncocytoid

         - Sarcomatoid

         - Chromophobe

         - Translocation

         - Collecting duct

         - Carcinoma associated with neuroblastoma

         - Renal cell carcinoma unclassified

   - Specimens/materials must be submitted for central review by Day 7

   - Patients must begin protocol therapy on AREN0321 by Day 14 after surgery or biopsy
   (surgery/biopsy is Day 0), unless medically contraindicated

   - Karnofsky performance status (PS) must be >= 50 for patients > 16 years if age and
   Lansky PS must be >= 50 for patients =< 16 years of age

   - Patients must not have received systemic chemotherapy or radiation therapy prior to
   treatment on this study UNLESS they were enrolled on the AREN0532 or AREN0533 studies
   and received prenephrectomy chemotherapy for what was originally presumed to be
   favorable histology Wilms tumor; additionally, patients with pediatric RCC who
   previously received chemotherapy for another type of malignancy (not the RCC) or
   non-malignant condition may enroll on the study

   - Total bilirubin =< 1.5 times upper limit of normal (ULN) for age

   - Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST] or
   serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase [ ALT]) < 2.5
   times ULN for age

   - Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by
   radionuclide angiogram

   - Female patients of childbearing age must have a negative pregnancy test

   - Female patients who are lactating must agree to stop breast-feeding

   - Sexually active patients of childbearing potential must agree to use effective
   contraception

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met